106896-57-5

Basic information

• Product Name: 3-Acetyl-1H-indole-4-carboxylic acid methyl ester
• Synonyms: 3-Acetyl-1H-indole-4-carboxylic acid methyl ester
• CAS NO: 106896-57-5
• Molecular Formula: C12H11NO3
• Molecular Weight: 217
• Mol File: 106896-57-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Acetyl-1H-indole-4-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Acetyl-1H-indole-4-carboxylic acid methyl ester(106896-57-5)
• EPA Substance Registry System: 3-Acetyl-1H-indole-4-carboxylic acid methyl ester(106896-57-5)

Safety Data

• Hazardous Substances Data: 106896-57-5(Hazardous Substances Data)

Upstream product

• 39830-66-5 methyl 1H-indole-4-carboxylate 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 

Relevant articles and documents

Ketone-Directed Cobalt(III)-Catalyzed Regioselective C2 Amidation of Indoles

An efficient cobalt(III)-catalyzed method for the direct C-H amidation of unprotected indoles for 2-amino indole scaffold construction has been developed. With dioxazolone as the amidating reagent, a variety of 2-amino indole derivatives were achieved in moderate to excellent yields using an organic acid as the additive and a ketone as the directing group.

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabet

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.